Neurogene (NGNE)
NASDAQ:NGNE
Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$27.85
-$0.86(-3.93%)
At close: 4:00 PM EST
$27.85
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$11.77 - $37.27
Previous CloseN/A
Volume20.02K
Average Volume (3M)225.72K
Market Cap
$422.09M
Enterprise Value$327.02M
Total Cash (Recent Filing)$269.01M
Total Debt (Recent Filing)$9.89M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
May 08, 2026EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding15,615,786
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-415.53
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$86.50Price Target Upside210.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Delivery AdvantageIntracerebroventricular delivery produced substantially greater vector presence in non-human primate brains than intrathecal delivery, suggesting a potential efficacy advantage through broader brain targeting.
Pivotal Trial Execution And SafetyCompletion of enrollment in the pivotal EMBOLDEN trial and ongoing dosing with no severe inflammatory safety events at the selected dose supports smoother regulatory review and clearer efficacy readouts.
Regulatory Progress And Clinical EvidenceBreakthrough Therapy Designation and FDA review of patient-level data and video documentation showing durable, multi-domain functional improvements strengthen the pathway toward approval and commercial reimbursement discussions.
Bears Say
Efficacy Interpretation UncertaintySkeptics' arguments that observed improvements in very young patients may reflect natural development rather than treatment effect introduce uncertainty for pivotal trial interpretation and approval prospects.
Historical High-dose Safety RiskA fatal inflammatory event in a prior high-dose cohort prompted a dosing strategy change and leaves a persistent safety overhang that could complicate regulatory confidence and market acceptance.
Valuation Sensitivity From Modeling RevisionA corrected modeling error that lowered an analyst price target highlights valuation sensitivity to share-count and other assumptions, which may weigh on the stock until fundamentals clarify.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $11.77 and its highest was $37.27 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $422.09M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is May 08, 2026 which is in 10 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Mar 24, 2026. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.239 by $0.119.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.3.
How many shares outstanding does Neurogene have?
Neurogene has 15,615,786 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.239. Following the earnings report the stock price went up 7.955%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.50 (210.59% Upside)
$86.50 (210.59% Upside)
Insider Transactions
Sold Shares
Worth $231.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.0%
Last 30 Days ▲ 31.7%
Last 30 Days ▲ 31.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-32.99%
Trailing 12-Months
Asset Growth
-14.05%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$86.50
▲(210.59% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
9.54% Insiders
6.59% Mutual Funds
0.28% Other Institutional Investors
73.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---